The underwritten offering of common stock and warrants by Vistagen Therapeutics could lead to dilution of existing shares. This is because the number of shares in circulation will increase, potentially leading to a decrease in the stock's price in the short term. However, the long-term impact will depend on how the company uses the funds raised from the offering.